Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Terminated

• Conditions: Precursor B-Cell Lymphoblastic Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Acute Lymphoblastic; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Lymphoblastic Lymphoma
• Interventions: Other: Diagnosed as ALL

• Registration Number: NCT01761682
• Lead Sponsor: Asan Medical Center

Brief Summary

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed Description

1. Acquisition of informed concent form

2. Data acquisition from medical record including

* demographic / disease-associated factors

* details of treatment, and its results

* complications during treatment

* genetic data

* survival outcome (upto 10 years)

3. Accumulation of data for 30 years

4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Study Timeline

• Study Start: 2013-01
• Study First Submitted: 2013-01-03
• Study First Submitted QC: 2013-01-03
• Study First Posted: 2013-01-07
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Status Verified: 2018-07
• Last Update Submitted: 2018-07-19
• Last Update Posted: 2018-07-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
• 15 years of age and over
• All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion Criteria

• Patients who refuse to give consent to registering

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Other ALL	Diagnosed as ALL	Diagnosed as ALL of other type, including Burkitt leukemia
Ph-ALL	Diagnosed as ALL	Diagnosed as ALL with Philadelphia-negative
Ph+ALL	Diagnosed as ALL	Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)

Primary Outcome Measures

Name	Time	Method
Overall survival	10 year

Secondary Outcome Measures

Name	Time	Method
Relapse-free survival	10 years	Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia
Event-free survival	10 years	Definition of events will be as 'relapse', 'death from any cause'. Relapse will be defined as hematologic relapse and molecular relapse, respectively when the patient is diagnosed as Philadelphia-positive acute lymphoblastic leukemia

Trial Locations

Locations (1)

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of